This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi-Maze deal abandonment a 'big win for patients,' US FTC says

( December 13, 2023, 20:38 GMT | Official Statement) -- MLex Summary: Sanofi and Maze's decision to walk away from their licensing agreement following the US Federal Trade Commission's suit to block the deal on Monday is a "big win for patients and an important victory for the FTC," Nate Soderstrom, acting deputy director of the FTC's Bureau of Competition, said in a statement. The licensing agreement for Maze's phase 1 therapy to treat Pompe disease would have bolstered Sanofi's monopoly on treatments for the disease, the FTC said, but without the deal, the companies can continue to compete on the merits and reduce costs and treatment burden for patients. Statement follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login